ReviewCurrent medical mycology2022
Review in Current medical mycology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Pharmacological advances inJournal of enzyme inhibition and medicinal chemistry · 2026Review
- Changes in Antimicrobial Resistance Patterns in Intensive Care Units Following the COVID-19 Pandemic: A 10-Year Retrospective Study from Türkiye.Antibiotics (Basel, Switzerland) · 2026Article
- Candidemia in Southern Poland (2017-2022): Multicenter Analysis of Species Distribution and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2026Article
- Article
- Review
- Characterization of COVID-19-Associated Candidemia Among Burn Patients.Journal of clinical laboratory analysis · 2025Article
- Challenges and future strategies for management of otomycosis caused byCurrent medical mycology · 2025Article
- Overcoming amphotericin B resistance inAntimicrobial agents and chemotherapy · 2024Article
- TheHealth science reports · 2024Article
- Review and Current Perspectives on DNA Topoisomerase I and II Enzymes of Fungi as Study Models for the Development of New Antifungal Drugs.Journal of fungi (Basel, Switzerland) · 2024Review
- Review
- The Emergence ofInfection and drug resistance · 2024Article
- Insights into the structure, function, and impact ofCurrent medical mycology · 2024Review
- Update of antimicrobial resistance in level III and IV health institutions in Colombia between January 2018 and December 2021Biomedica : revista del Instituto Nacional de Salud · 2023Article
- In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against FourPharmaceutics · 2023Article
- Emergence of highly resistantFrontiers in public health · 2023Article
- Secreted aspartyl protease 3 regulated by the Ras/cAMP/PKA pathway promotes the virulence ofFrontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since its first emergence in December 2019, due to its fast distribution throughout the world, SARS-COV-2 become a global concern. With the extremely increased number of hospitalized patients, this situation provided a potential basis for the transmission of nosocomial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.